This blend contains three peptides studied for tissue repair mechanisms in preclinical research. GHK-Cu is a naturally occurring tripeptide-copper complex present in human plasma that declines with age, measuring approximately 200 ng/mL at age 20 and declining to 80 ng/mL by age 60. BPC-157 is a pentadecapeptide isolated from gastric juice that demonstrates stability and resistance to enzymatic degradation. TB-500 is a synthetic peptide derived from thymosin beta-4, an actin-binding protein found in high concentrations in platelets and wound fluid. Preclinical studies examine these peptides' effects on wound healing phases including angiogenesis, cellular migration, and collagen deposition. Research has been conducted primarily in cell cultures and animal models, with limited human clinical data available.